ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway.

Jacobi, Oded; Ross, Jeffrey S; Goshen-Lago, Tal; Haddad, Riad; Moore, Assaf; Sulkes, Aaron; Brenner, Baruch; Ben-Aharon, Irit

Jacobi, Oded; Ross, Jeffrey S; Goshen-Lago, Tal; Haddad, Riad; Moore, Assaf; Sulkes, Aaron; Brenner, Baruch; Ben-Aharon, Irit.

Afiliação

Jacobi O; Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tiqwa, Israel, jacobi.oded@gmail.com.
Ross JS; Foundation Medicine Inc., Cambridge, Massachusetts, USA.
Goshen-Lago T; Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tiqwa, Israel.
Haddad R; Department of Surgery, Carmel Medical Center, Haifa, Israel.
Moore A; Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tiqwa, Israel.
Sulkes A; Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel.
Brenner B; Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tiqwa, Israel.
Ben-Aharon I; Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel.

Oncol Res Treat ; 44(1-2): 20-27, 2021.

Article em En | MEDLINE | ID: mdl-33279901

Assuntos

Neoplasias dos Ductos Biliares; Colangiocarcinoma; Neoplasias Gastrointestinais; Neoplasias dos Ductos Biliares/tratamento farmacológico; Neoplasias dos Ductos Biliares/genética; Ductos Biliares Intra-Hepáticos; Colangiocarcinoma/tratamento farmacológico; Colangiocarcinoma/genética; Humanos; Mutação; Receptor ErbB-2/genética; Transdução de Sinais; Trastuzumab

Palavras-chave

Cholangiocarcinoma; ERBB2; HER2; Targeted therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Colangiocarcinoma / Neoplasias Gastrointestinais Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google